Stock Track | Altimmune Soars 6.69% After-hours on Positive Pembrolizumab Subcutaneous Formulation Phase 3 Data

Stock Track2024-11-20

Altimmune, Inc. (ALT) shares surged 6.69% in after-hours trading on Tuesday, following positive topline results from Merck's Phase 3 MK-3475A-D77 trial evaluating the subcutaneous administration of pembrolizumab (Keytruda) together with Altimmune's berahyaluronidase alfa (ALT-B4) in combination with chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC).

The trial met its dual primary pharmacokinetic endpoints, demonstrating non-inferior exposure of the subcutaneous pembrolizumab formulation compared to intravenous Keytruda when administered with chemotherapy. Secondary endpoints of efficacy and safety were generally consistent between the two treatment arms.

These positive results suggest that the subcutaneous pembrolizumab formulation, if approved, could improve the treatment experience for patients by reducing administration time and increasing access compared to intravenous infusion. Merck plans to discuss the data with regulatory authorities worldwide as soon as possible.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment